Neurent Medical lands €25M debt facility to scale chronic rhinitis device
What's the deal? Neurent Medical has secured a €25 million growth debt facility from Claret Capital PartnersDealroom has a profile for this one. Try Dealroom →, the company announced on September 9, 2026. The financing will fund commercial expansion of its NEUROMARK System, boost sales and marketing, and strengthen the company's balance sheet.
What's the endgame? Neurent Medical, based in Galway, Ireland, with US operations in Braintree, Massachusetts, treats chronic inflammatory sinonasal diseases. Its NEUROMARK System uses impedance-controlled radiofrequency technology to target hyperactive posterior nasal nerves, offering relief from chronic rhinitis symptoms.
Why now? The debt facility follows Neurent Medical's €62.5 million Series C, completed earlier this year. Debt allows the company to extend its runway with minimal dilution to shareholders.
What they're saying: "The facility provides significant financial flexibility while allowing us to continue executing our growth strategy with minimal dilution to shareholders," said chief executive officer Brian Shields. The deal deepens an existing relationship with Claret Capital Partners.
Daniel Mallon, principal at Claret, cited the company's "exceptional progress in establishing NEUROMARK as a leading treatment option for chronic rhinitis."
The signal: Growth debt is increasingly the tool of choice for medtech scaleups that want capital without ceding equity. Claret Capital Partners, Europe's largest independent growth debt fund manager, has deployed over €1.5 billion across more than 210 companies since 2013 — a sign of how deep the appetite runs for lending to commercial-stage life sciences firms.
Image credit: Neurent Medical
